Is Tango Therapeutics (TNGX) Overpriced Following a 200% Increase in the Past Year? An Updated Analysis of Its Valuation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 14 2025
0mins
Should l Buy TNGX?
Source: Yahoo Finance
Tango Therapeutics Performance: Tango Therapeutics (TNGX) has seen a significant stock increase of approximately 200% this year and over 300% in the past year, driven by investor interest in its oncology pipeline.
Valuation Concerns: Despite its strong performance, Tango Therapeutics is trading at a high price-to-sales ratio of 18.9, which is well above industry averages, raising questions about whether the stock is overvalued or if future growth is already priced in.
Risks to Growth: Potential setbacks in clinical trials or slower revenue growth could challenge the optimistic valuation, indicating that investors are currently paying a premium based on anticipated future success rather than current profits.
Investment Insights: The article suggests exploring other healthcare stocks and highlights key rewards and risks associated with investing in Tango Therapeutics, emphasizing the importance of thorough research before making investment decisions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TNGX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TNGX
Wall Street analysts forecast TNGX stock price to fall
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 19.210
Low
12.00
Averages
13.67
High
15.00
Current: 19.210
Low
12.00
Averages
13.67
High
15.00
About TNGX
Tango Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering precision medicine for the treatment of cancer. The Company's novel small molecules are designed to be selectively active in cancer cells with specific genetic alterations, killing those cancer cells while sparing normal cells. It is also extending its target space beyond the classic, cell-autonomous effects of tumor suppressor gene loss. It is engaged in developing two methylthioadenosine (MTA)-cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors: TNG462 for non- central nervous system (CNS) cancers, including pancreatic and lung cancer, and TNG456, brain-penetrant PRMT5 inhibitor, for CNS cancers, including glioblastoma (GBM). Its TNG260 is a first-in-class Co-repressor of Repressor Element-1 Silencing Transcription (CoREST) inhibitor, which in preclinical studies reversed the immune evasion effect of STK11 loss-of-function mutations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Analysis of Insider Stock Transaction at Tango Therapeutics
- Insider Stock Sale: Adam Crystal, President of R&D at Tango Therapeutics, sold 20,251 shares on March 5, 2026, for a total of $303,765, indicating a continued liquidity management strategy within the company.
- Ownership Proportion Change: This transaction represented 15.24% of Crystal's direct holdings, significantly higher than his earlier median of 3.42%, suggesting an increasing trend in his share sales in recent transactions.
- Company Financial Overview: Tango Therapeutics reported a trailing twelve-month revenue of $62.38 million, with a net income of -$101.59 million; however, its stock price surged 1,220% over the past year, reflecting strong market confidence in its cancer treatment drugs.
- Clinical Trial Progress: The company achieved positive results in clinical trials for MTAP-deleted pancreatic cancer, driving a 36% stock price increase, while holding $343 million in cash, ensuring operational stability during its clinical phase.
See More
Tango Therapeutics Executive Sells Shares Amid Stock Surge
- Insider Sale Details: Adam Crystal, President of R&D at Tango Therapeutics, sold 20,251 shares on March 5, 2026, for approximately $304,000 at an average price of $15 per share, representing 15.24% of his direct holdings, reducing his position from 132,873 to 112,622 shares.
- Transaction Context: The sale involved only direct ownership without any trades through indirect entities or derivatives, aligning with Crystal's historical pattern of scheduled sales, indicating his awareness of stock price fluctuations.
- Market Reaction: On the same day as the sale, Tango Therapeutics' stock surged 36% following strong Q4 results and pipeline updates, highlighting the market's positive response to clinical data, although insider selling may raise investor concerns.
- Financial Position: Tango Therapeutics holds $343 million in cash, providing a runway into 2028, which offers significant insulation against the inherent risks of clinical-stage oncology, especially as a single failed trial can erase years of gains.
See More
B. Riley Increases Target Price for TANGO THERAPEUTICS INC to $21, Up from $14
Company Overview: Tango Therapeutics is a biotechnology company focused on developing innovative cancer therapies.
Stock Price Increase: Analyst B. Riley has raised the target price for Tango Therapeutics' stock from $14 to $21, indicating a positive outlook for the company's future performance.
See More
Biotech Investment Revives as Institutional Capital Flows Back
- Capital Flow Trend: In early 2026, institutional investors significantly increased financing activities in the biotech sector, indicating a strong interest in clinical-stage companies with validated science, which is expected to drive industry recovery and attract more investments.
- Precision Medicine Market Outlook: The global oncology precision medicine market is projected to reach $303 billion by 2035, growing at approximately 9% annually, providing substantial market opportunities for companies focused on precision medicine, particularly in cancer treatment.
- Oncolytics Biotech New Data: Oncolytics Biotech is set to present new mechanistic and translational data for its drug pelareorep at the upcoming AACR Annual Meeting, with preliminary results indicating that the drug may enhance tumor sensitivity to immunotherapy, potentially altering treatment strategies.
- OS Therapies Accelerated Approval Progress: OS Therapies' OST-HER2 immunotherapy has received an elevation to a Type B meeting with the FDA, signaling a transition to accelerated approval discussions following the submission of its clinical data package, which could provide a significant competitive advantage in the market.
See More
Wall Street Analysts Adjust MU Stock Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their outlook on MU stock, indicating varying perspectives on the company's future, which could influence investor decisions and market sentiment.
- Market Reaction Expectations: Although specific rating changes are not detailed in the report, analysts' opinions typically have a direct impact on stock prices, prompting investors to closely monitor these shifts for informed investment choices.
- Lack of Investment Advice: The report notes that Benzinga does not provide investment advice, emphasizing the importance for investors to rely on their own research and analysis rather than solely on analysts' ratings.
- Diverse Information Sources: To gain a more comprehensive view of analyst rating changes, investors are encouraged to visit Benzinga's analyst ratings page for the latest upgrades and downgrades information.
See More
Tango Therapeutics Grants Stock Options and RSUs to New Employee
- Stock Option Grant: Tango Therapeutics granted 367,500 stock options to a new employee on February 2, 2026, with an exercise price of $11.94 per share, reflecting the company's commitment to incentivizing key talent and enhancing employee retention.
- Restricted Stock Units: Additionally, 60,000 restricted stock units (RSUs) were awarded, with 20,000 shares vesting on February 1, 2027, further strengthening the long-term incentive structure and promoting employee engagement and loyalty.
- Inducement Plan Context: The grants are made under Tango Therapeutics' 2023 Inducement Plan, specifically designed to attract new employees, showcasing the company's strategic focus on talent acquisition to drive future innovation and growth.
- Long-Term Incentive Structure: The staggered vesting schedule for stock options and RSUs over the next three years ensures that employees remain committed to the company while fostering a sense of ownership and participation in the company's long-term success.
See More
Analysis of Insider Stock Transaction at Tango Therapeutics
- Insider Stock Sale: Adam Crystal, President of R&D at Tango Therapeutics, sold 20,251 shares on March 5, 2026, for a total of $303,765, indicating a continued liquidity management strategy within the company.
- Ownership Proportion Change: This transaction represented 15.24% of Crystal's direct holdings, significantly higher than his earlier median of 3.42%, suggesting an increasing trend in his share sales in recent transactions.
- Company Financial Overview: Tango Therapeutics reported a trailing twelve-month revenue of $62.38 million, with a net income of -$101.59 million; however, its stock price surged 1,220% over the past year, reflecting strong market confidence in its cancer treatment drugs.
- Clinical Trial Progress: The company achieved positive results in clinical trials for MTAP-deleted pancreatic cancer, driving a 36% stock price increase, while holding $343 million in cash, ensuring operational stability during its clinical phase.
See More
Tango Therapeutics Executive Sells Shares Amid Stock Surge
- Insider Sale Details: Adam Crystal, President of R&D at Tango Therapeutics, sold 20,251 shares on March 5, 2026, for approximately $304,000 at an average price of $15 per share, representing 15.24% of his direct holdings, reducing his position from 132,873 to 112,622 shares.
- Transaction Context: The sale involved only direct ownership without any trades through indirect entities or derivatives, aligning with Crystal's historical pattern of scheduled sales, indicating his awareness of stock price fluctuations.
- Market Reaction: On the same day as the sale, Tango Therapeutics' stock surged 36% following strong Q4 results and pipeline updates, highlighting the market's positive response to clinical data, although insider selling may raise investor concerns.
- Financial Position: Tango Therapeutics holds $343 million in cash, providing a runway into 2028, which offers significant insulation against the inherent risks of clinical-stage oncology, especially as a single failed trial can erase years of gains.
See More
B. Riley Increases Target Price for TANGO THERAPEUTICS INC to $21, Up from $14
Company Overview: Tango Therapeutics is a biotechnology company focused on developing innovative cancer therapies.
Stock Price Increase: Analyst B. Riley has raised the target price for Tango Therapeutics' stock from $14 to $21, indicating a positive outlook for the company's future performance.
See More
Biotech Investment Revives as Institutional Capital Flows Back
- Capital Flow Trend: In early 2026, institutional investors significantly increased financing activities in the biotech sector, indicating a strong interest in clinical-stage companies with validated science, which is expected to drive industry recovery and attract more investments.
- Precision Medicine Market Outlook: The global oncology precision medicine market is projected to reach $303 billion by 2035, growing at approximately 9% annually, providing substantial market opportunities for companies focused on precision medicine, particularly in cancer treatment.
- Oncolytics Biotech New Data: Oncolytics Biotech is set to present new mechanistic and translational data for its drug pelareorep at the upcoming AACR Annual Meeting, with preliminary results indicating that the drug may enhance tumor sensitivity to immunotherapy, potentially altering treatment strategies.
- OS Therapies Accelerated Approval Progress: OS Therapies' OST-HER2 immunotherapy has received an elevation to a Type B meeting with the FDA, signaling a transition to accelerated approval discussions following the submission of its clinical data package, which could provide a significant competitive advantage in the market.
See More
Wall Street Analysts Adjust MU Stock Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their outlook on MU stock, indicating varying perspectives on the company's future, which could influence investor decisions and market sentiment.
- Market Reaction Expectations: Although specific rating changes are not detailed in the report, analysts' opinions typically have a direct impact on stock prices, prompting investors to closely monitor these shifts for informed investment choices.
- Lack of Investment Advice: The report notes that Benzinga does not provide investment advice, emphasizing the importance for investors to rely on their own research and analysis rather than solely on analysts' ratings.
- Diverse Information Sources: To gain a more comprehensive view of analyst rating changes, investors are encouraged to visit Benzinga's analyst ratings page for the latest upgrades and downgrades information.
See More
Tango Therapeutics Grants Stock Options and RSUs to New Employee
- Stock Option Grant: Tango Therapeutics granted 367,500 stock options to a new employee on February 2, 2026, with an exercise price of $11.94 per share, reflecting the company's commitment to incentivizing key talent and enhancing employee retention.
- Restricted Stock Units: Additionally, 60,000 restricted stock units (RSUs) were awarded, with 20,000 shares vesting on February 1, 2027, further strengthening the long-term incentive structure and promoting employee engagement and loyalty.
- Inducement Plan Context: The grants are made under Tango Therapeutics' 2023 Inducement Plan, specifically designed to attract new employees, showcasing the company's strategic focus on talent acquisition to drive future innovation and growth.
- Long-Term Incentive Structure: The staggered vesting schedule for stock options and RSUs over the next three years ensures that employees remain committed to the company while fostering a sense of ownership and participation in the company's long-term success.
See More
